氟喹诺酮类药物与细胞壁活性药物的比较杀菌率。
Comparative killing rates of fluoroquinolones and cell wall-active agents.
作者信息
Fung-Tomc J C, Gradelski E, Valera L, Kolek B, Bonner D P
机构信息
Department of Microbiology, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492, USA.
出版信息
Antimicrob Agents Chemother. 2000 May;44(5):1377-80. doi: 10.1128/AAC.44.5.1377-1380.2000.
Abstract
Killing rates of fluoroquinolones, beta-lactams, and vancomycin were compared against Enterobacteriaceae, Staphylococcus aureus, pneumococci, streptococci, and Enterococcus faecalis. The times required for fluoroquinolones to decrease viability by 3 log(10) were 1.5 h for Enterobacteriaceae, 4 to 6 h for staphylococci, and >/=6 h for streptococci and enterococci. Thus, the rate of killing by fluoroquinolones is organism group dependent; overall, they killed more rapidly than beta-lactams and vancomycin.
摘要
比较了氟喹诺酮类、β-内酰胺类和万古霉素对肠杆菌科细菌、金黄色葡萄球菌、肺炎球菌、链球菌和粪肠球菌的杀菌率。氟喹诺酮类使细菌活力降低3个对数（10）所需时间，对肠杆菌科细菌为1.5小时，对葡萄球菌为4至6小时，对链球菌和肠球菌则≥6小时。因此，氟喹诺酮类的杀菌速率取决于细菌种类；总体而言，它们的杀菌速度比β-内酰胺类和万古霉素更快。
相似文献
1
Comparative killing rates of fluoroquinolones and cell wall-active agents.氟喹诺酮类药物与细胞壁活性药物的比较杀菌率。
Antimicrob Agents Chemother. 2000 May;44(5):1377-80. doi: 10.1128/AAC.44.5.1377-1380.2000.
2
Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.新型去氟（6）喹诺酮BMS-284756、氟喹诺酮类、万古霉素和β-内酰胺类的比较杀菌动力学
Int J Antimicrob Agents. 2001 Jul;18(1):43-8. doi: 10.1016/s0924-8579(01)00343-0.
3
The fluoroquinolones exert a reduced rate of kill against Enterococcus faecalis.氟喹诺酮类药物对粪肠球菌的杀菌速率降低。
J Pharm Pharmacol. 1991 Jul;43(7):492-4. doi: 10.1111/j.2042-7158.1991.tb03520.x.
4
Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.替考拉宁、达托霉素、雷莫拉宁、万古霉素和PD127,391对革兰氏阳性球菌血液分离株的体外活性比较
Antimicrob Agents Chemother. 1992 Jul;36(7):1570-2. doi: 10.1128/AAC.36.7.1570.
5
The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.克林沙星与其他抗菌药物对万古霉素敏感和耐药肠球菌的体外比较活性。
Chemotherapy. 1996 Jul-Aug;42(4):235-9. doi: 10.1159/000239449.
6
Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin.替加环素推定分类的万古霉素药敏试验结果分析。
J Clin Microbiol. 2015 Aug;53(8):2727-30. doi: 10.1128/JCM.00611-15. Epub 2015 May 27.
7
Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci.替考拉宁与万古霉素单独及联合利福平、氨基糖苷类药物对葡萄球菌和肠球菌的体外比较活性
Antimicrob Agents Chemother. 1984 Apr;25(4):411-2. doi: 10.1128/AAC.25.4.411.
8
In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci.新型喹诺酮抗菌剂司帕沙星（AT-4140和CI-978）对嗜血杆菌和革兰氏阳性球菌的体外活性。
Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):355-60. doi: 10.1016/0732-8893(91)90028-e.
9
Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model.洛美沙星在药代动力学体外模型中的抗菌活性
Antimicrob Agents Chemother. 1990 Jun;34(6):1107-11. doi: 10.1128/AAC.34.6.1107.
10
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.奥利万星及对照药物对金黄色葡萄球菌、粪肠球菌和屎肠球菌的时间杀菌动力学
J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.
引用本文的文献
1
Successful fluoroquinolone-based salvage therapy in the conservative management of refractory infective endocarditis caused by in an elderly patient: a case report.老年患者中基于氟喹诺酮类药物的成功挽救治疗对耐碳青霉烯类肺炎克雷伯菌引起的难治性感染性心内膜炎的保守治疗：一例报告
Oxf Med Case Reports. 2025 Aug 11;2025(8):omaf127. doi: 10.1093/omcr/omaf127. eCollection 2025 Aug.
2
Evaluation the kill rate and mutant selection window of danofloxacin against Actinobacillus pleuropneumoniae in a peristaltic pump model.评价在蠕动泵模型中丹氟沙星对胸膜肺炎放线杆菌的杀菌率和突变选择窗。
BMC Vet Res. 2024 Jun 3;20(1):241. doi: 10.1186/s12917-024-04016-9.
3
PK-PD integration of enrofloxacin and cefquinome alone and in combination against using an dynamic model.恩诺沙星和头孢喹肟单独及联合使用时基于动态模型的药代动力学-药效学整合研究（针对[此处原文缺失相关内容]）
Front Pharmacol. 2023 Oct 6;14:1226936. doi: 10.3389/fphar.2023.1226936. eCollection 2023.
4
Probing the Mechanism of LAL-32, a Gold Nanoparticle-Based Antibiotic Discovered through Small Molecule Variable Ligand Display.探索LAL-32的作用机制，一种通过小分子可变配体展示发现的基于金纳米颗粒的抗生素。
Bioconjug Chem. 2017 Jul 19;28(7):1807-1810. doi: 10.1021/acs.bioconjchem.7b00199. Epub 2017 Jun 27.
5
Population Density Modulates Drug Inhibition and Gives Rise to Potential Bistability of Treatment Outcomes for Bacterial Infections.种群密度调节药物抑制作用，并导致细菌感染治疗结果出现潜在的双稳态。
PLoS Comput Biol. 2016 Oct 20;12(10):e1005098. doi: 10.1371/journal.pcbi.1005098. eCollection 2016 Oct.
6
Modeling the growth dynamics of multiple Escherichia coli strains in the pig intestine following intramuscular ampicillin treatment.建模肌肉注射氨苄青霉素后猪肠道内多种大肠杆菌菌株的生长动力学。
BMC Microbiol. 2016 Sep 6;16(1):205. doi: 10.1186/s12866-016-0823-3.
7
Pharmacodynamic modelling of in vitro activity of tetracycline against a representative, naturally occurring population of porcine Escherichia coli.四环素对具有代表性的自然存在的猪源大肠杆菌群体的体外活性的药效学建模。
Acta Vet Scand. 2015 Nov 24;57:79. doi: 10.1186/s13028-015-0169-0.
8
Translating slow-binding inhibition kinetics into cellular and in vivo effects.将慢结合抑制动力学转化为细胞和体内效应。
Nat Chem Biol. 2015 Jun;11(6):416-23. doi: 10.1038/nchembio.1796. Epub 2015 Apr 20.
9
The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.铜绿假单胞菌对环丙沙星耐药性的发展涉及多个反应阶段和多种蛋白质。
Antimicrob Agents Chemother. 2010 Nov;54(11):4626-35. doi: 10.1128/AAC.00762-10. Epub 2010 Aug 9.
10
Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus.金黄色葡萄球菌中基于机制的氟喹诺酮耐药性药效学模型。
Antimicrob Agents Chemother. 2006 Sep;50(9):2957-65. doi: 10.1128/AAC.00736-05.
本文引用的文献
1
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.加替沙星与其他喹诺酮类及非喹诺酮类药物相比的抗肺炎球菌活性。
J Antimicrob Chemother. 1999 May;43(5):645-9. doi: 10.1093/jac/43.5.645.
2
Bactericidal properties of moxifloxacin and post-antibiotic effect.
J Antimicrob Chemother. 1999 May;43 Suppl B:43-9. doi: 10.1093/jac/43.suppl_2.43.
3
Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.曲伐沙星治疗实验性葡萄球菌或链球菌性心内膜炎的疗效。
Antimicrob Agents Chemother. 1999 Jan;43(1):77-84. doi: 10.1128/AAC.43.1.77.
4
In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.曲伐沙星与其他抗生素联合对肠球菌的体外活性
Diagn Microbiol Infect Dis. 1997 Dec;29(4):233-9. doi: 10.1016/s0732-8893(97)00161-2.
5
Bactericidal index: a new way to assess quinolone bactericidal activity in vitro.杀菌指数：一种体外评估喹诺酮类杀菌活性的新方法。
J Antimicrob Chemother. 1997 Jun;39(6):713-7. doi: 10.1093/jac/39.6.713.
6
Bactericidal activity of trovafloxacin (CP-99,219).曲伐沙星（CP-99,219）的杀菌活性。
J Antimicrob Chemother. 1996 Dec;38(6):1061-6. doi: 10.1093/jac/38.6.1061.
7
Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.产超广谱头孢菌素的阴沟肠杆菌耐药变异体的差异。
Antimicrob Agents Chemother. 1996 May;40(5):1289-93. doi: 10.1128/AAC.40.5.1289.
8
Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci.胃肠外给予司帕沙星与头孢曲松治疗对青霉素敏感和耐药链球菌所致实验性心内膜炎的比较。
Antimicrob Agents Chemother. 1994 Dec;38(12):2683-8. doi: 10.1128/AAC.38.12.2683.
9
10
The fluoroquinolones exert a reduced rate of kill against Enterococcus faecalis.氟喹诺酮类药物对粪肠球菌的杀菌速率降低。
J Pharm Pharmacol. 1991 Jul;43(7):492-4. doi: 10.1111/j.2042-7158.1991.tb03520.x.
Zotero 插件